ALNOV:EPA
Novacyt SA
€0.43
arrow_upward
+1.66%(+0.0070) 1D
Nov 10, 5:35:24 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNOV...
Open
€0.42
High
€0.43
Low
€0.42
Mkt. cap
31.28M
Avg. vol.
173.25K
Volume
81.77K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.38
Shares outstanding
72.59M
No. of employees
228
Open
€0.42
High
€0.43
Low
€0.42
Mkt. cap
31.28M
Avg. vol.
173.25K
Volume
81.77K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.38
Shares outstanding
72.59M
No. of employees
228
News stories
From web sources and news partners
StreetInsider
·
30 minutes ago
Global S&P Futures mixed to up in premarket
Yahoo Finance
·
1 hour ago
Is the S&P 500 Heading for a Correction?
FOX 2
·
57 minutes ago
US stocks fall after a discouraging update on inflation
Investor's Business Daily
·
23 minutes ago
Dow Leader Amazon Approaches Latest Buy Point As Ferrari Races Higher On Formula 1 Strength
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees228
FoundedJul 3, 2006
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitenovacyt.com